Recovery-by-eHealth
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04675684 |
Recruitment Status :
Not yet recruiting
First Posted : December 19, 2020
Last Update Posted : March 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression | Behavioral: Recovery-group | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 130 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants will be 1:1 randomized into either a recovery group (experimental) or a control group (no intervention). |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Recovery-by-eHealth: A Complex Intervention Aiding Recovery in Patients With Depression Discharged From a Psychiatric Outpatient Clinic - a 12 Months Randomized Controlled Clinical Trial |
Estimated Study Start Date : | August 1, 2021 |
Estimated Primary Completion Date : | August 1, 2024 |
Estimated Study Completion Date : | August 1, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Recovery-group
The recovery group consists of:
|
Behavioral: Recovery-group
The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
Other Name: Intervention-group |
No Intervention: Control-group
The control group consists of usual treatment at their General Practitioner and / or Private Practicing Psychiatrist.
|
- Personal recovery self-assessed by the Brief INSPIRE-O scale [ Time Frame: 12 months ]Difference between the two groups in return to personal recovery from baseline until 12 months after baseline measured whit Brief INSPIRE-O's 5-item self-rated measure of personal recovery.
- Recovery support self-assessed by the INSPIRE scale [ Time Frame: 12 months ]Difference between the two groups in return to recovery support from a clinician/worker from baseline until 12 months after baseline measured with Brief INSPIRE's 5-item self-rated measure of recovery support from a clinician/worker.
- Depressive symptoms self-assessed by the Hamilton Depression Rating 6-item Scale (Ham-D6) [ Time Frame: 12 months ]Difference between the two groups in return to symptoms of depression from baseline until 12 months after baseline measured with Hamilton Depression Rating Scale consisting of 6 items. Total scores from zero (no depression) to 22 (most severe depression).
- Wellbeing self-assessed by the WHO-5 scale [ Time Frame: 12 months ]Difference between the two groups in return to wellbeing from baseline until 12 months after baseline measured with WHO-5's wellbeing self-assessed scale consisting of 5 items.
- Number of relapses of depression blindly-assessed by the Mini International Neuropsychiatric Interview [ Time Frame: 12 months ]Difference between the two groups in return to number of relapses of depression from baseline until 12 months after baseline measured with a short, structured clinical diagnostic interview based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- Adherence to medication according to Medicine Adherence Rating Scale (MARS) [ Time Frame: 12 months ]Difference between the two groups in return to medication adherence from baseline until 12 months after baseline from patients interviews and patient records (explorative outcome).
- Rate of hospital re-admissions [ Time Frame: 12 months ]Difference between the two groups in return to rate of hospital re-admissions during the project period from patient interviews and patient records (explorative outcome).
- Perceived stress self-assessed by the Perceived Stress Scale (PSS) [ Time Frame: 12 months ]Difference between the two groups in return to perceived stress according to Cohen's Perceived Stress Scale (PSS) from baseline and until 12 months after baseline (explorative outcome).
- Repetitive negative thinking and anxiety self-assessed by the Perseverative Thinking Questionnaire (PTQ) [ Time Frame: 12 months ]Difference between the two groups in return to repetitive negative thinking and anxiety according to the Perseverative Thinking Questionnaire (PTQ) from baseline and until 12 months after baseline (explorative outcome).
- Blood level [ Time Frame: 12 months ]Difference between the two groups in return to the following blood levels: C-Reactive Protein (CRP), total-cholesterol, Low-Density Lipoprotein (LDL), Low-Density Lipoprotein (HDL), and triglyceride (mg/dL) from baseline until 12 months after baseline from patient records (explorative outcome).
- Weight (kg) [ Time Frame: 12 months ]Difference between the two groups in return to weight (kg) from baseline until 12 months after baseline. The participants weight (kg) and height (meter) will be combined to calculate their Body Mass Index (kg/m^2) (explorative outcome).
- Height (meter) [ Time Frame: 12 months ]Difference between the two groups in return to height (meter) from baseline until 12 months after baseline. The participants weight (kg) and height (meter) will be combined to calculate their Body Mass Index (kg/m^2) (explorative outcome).
- Blood pressure [ Time Frame: 12 months ]Difference between the two groups in return to blood pressure (mm Hg) from baseline until 12 months after baseline (explorative outcome).
- Blood level [ Time Frame: 12 months ]Difference between the two groups in return to Thyrotropin (TSH; mIU/L) from baseline until 12 months after baseline (explorative outcome).
- Blood level [ Time Frame: 12 months ]Difference between the two groups in return to Vitamin D (nmol/L) from baseline until 12 months after baseline (explorative outcome).
- Blood level [ Time Frame: 12 months ]Difference between the two groups in return to Hemoglobin A1c (HbA1c; mmol/mol) from baseline until 12 months after baseline (explorative outcome).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 18 years
- Treated for depression at the IAOC for minimum 6 months and with a planned continued treatment in primary health care
Exclusion Criteria:
- Psychotic depression at inclusion
- Dementia or other organic brain disorders
- Alcohol substance abuse that is expected to interfere with the study procedures
- INSPIRE-O score > 65 at inclusion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04675684
Contact: Anne Sofie Aggestrup, MSc, PhD student | +45 40149422 | anne.sofie.aggestrup@regionh.dk | |
Contact: Klaus Martiny, Professor | +45 38647102 | klaus.martiny@regionh.dk |
Responsible Party: | Anne Sofie Aggestrup, MSc, PhD student, Mental Health Centre Copenhagen |
ClinicalTrials.gov Identifier: | NCT04675684 |
Other Study ID Numbers: |
H-20076894 |
First Posted: | December 19, 2020 Key Record Dates |
Last Update Posted: | March 18, 2021 |
Last Verified: | March 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Recovery Depression Prevention Physical health |
Mental health Randomized Controlled Trial Mixed methods Intersectoral collaboration |
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders |